Artemis Medicare Q1 FY27 Results: Profit Up, Approves ₹160-180 Cr Expansion
Artemis Medicare reported Q1 FY27 results with standalone profit after tax at ₹310.51 crore and consolidated profit after tax at ₹314.43 crore. The company approved a ₹160-180 crore expansion for Tower IV at its Gurugram hospital, adding over 200 beds for specialized pediatric and women's health services. The expansion is expected within two years.
The financial results show a positive performance, and the substantial capital expenditure for expansion signifies a major strategic move that could significantly impact future revenue and market position.
The company reported increased profits and announced a significant expansion plan, indicating positive future growth prospects.
Artemis Medicare Services Limited announced its un-audited financial results for the quarter ended June 30, 2026. The company reported a profit after tax of ₹310.51 crore on a standalone basis and ₹314.43 crore on a consolidated basis for the quarter. The Board of Directors also approved an expansion plan for Tower IV at its flagship hospital in Gurugram. This expansion will add over 200 beds, focusing on quaternary pediatric care and advanced gynecology & women's health services. The project is estimated to cost between ₹160 to ₹180 crore and is expected to be completed within two years, financed through internal accruals and debt.
The company's revenue from operations for the quarter stood at ₹2820.09 crore (standalone) and ₹2873.23 crore (consolidated). The board meeting commenced at 3:30 PM and concluded at 4:32 PM on August 3, 2026. The financial results were reviewed by the Audit Committee and approved by the Board, with the statutory auditors, T R Chadha & Co LLP, issuing an unmodified conclusion. The full financial results will be available on the websites of NSE, BSE, and the company.
What to do with a filing like this
Artemis Medicare Services Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Artemis Medicare Services Limited. Read the original for the full detail.